Return on drug R&D dropping


The pharma industry is getting less and less return on investment in R&D, according to a report. But the trend seems to be bottoming out and – on a more positive note – there are more compounds going into late stage development.

Consultants Deloitte and data firm Thomson Reuters looked at twelve pharma companies and estimated the projected financial returns from the R&D investment in their late stage pipeline, comprising products that are in Phase III trials, but have yet to be approved for marketing.

They found that the return fell from 7.7% in 2010–11 to 7.2% in 2011–12, but the number of number of compounds entering the late stage pipeline more than doubled from 35 to 78.

Overall, the results present a mixed bag for the optimists. The number of approvals increased from 32 to 41, but the total forecast sales of all approvals fell by a third, from $309 billion (£192 billion) to $211 billion. Meanwhile, the total forecast sales of candidates in late stage pipelines declined from $1,370 billion in 2010 to $1,050 billion in 2012.


Related Content

Roadmap to reward pharma for creating new antibiotics unveiled

19 May 2015 News and Analysis

news image

Report recommends large up-front payments and an innovation fund for blue skies research to tackle microbial resistance

The hunt for innovation

31 January 2014 Premium contentFeature

news image

Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom

Most Commented

A risky business

28 August 2015 In the Pipeline

news image

Graduate research is likely the most risky time of a chemist’s career, says Derek Lowe

Ultralight solar cells designed to drive drones

24 August 2015 Research

news image

Researchers have shown perovskite solar cells just 3μm thick can power miniature model aircraft